ReviewScience advances2026
Reappraising the topology of cell-free fetal DNA in maternal blood toward improved prenatal genetic diagnostics.
Review in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Noninvasive prenatal testing (NIPT) is a pregnancy screening test that analyses cell-free fetal DNA (cffDNA) in maternal plasma to detect fetal genetic abnormalities during pregnancy. Earlier and safer detection of fetal genetic abnormalities facilitated by NIPT has markedly transformed maternal-fetal medicine. However, NIPT is currently limited to be only a screening test due to fundamental biological bottlenecks, namely, the small proportion of cffDNA compared to cell-free maternal DNA in maternal plasma, the challenge to reliably distinguish between fetal and maternal DNA, and discordance between cffDNA and the true fetal genotype. Despite millions of NIPT being conducted each year, the exact origin and structural topology of cffDNA remain unexpectedly unclear. Elucidating the origin and structure of cffDNA could unlock new technological advances that address the current bottlenecks limiting NIPT toward realizing the full potential of state-of-the-art sequencing approaches for NIPT. In this Review, we critically discuss current cffDNA knowledge, including its origin, release into maternal blood circulation, and structures relevant to contemporary NIPT.
Indexed as
Identifiers
42826178What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.